TAFRO subtype of idiopathic multicentric Castleman disease in a 22-year-old man Authors: Steven Rowe, Brandon Wayne Collins, Amrah Pirzada, Neal Manning, Luke Y.C. Chen Published: 2024 KEY POINTS The syndrome of thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly (TAFRO) is a rare subtype of idiopathic multicentric Castleman disease. The syndrome of thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly (TAFRO) is a rare subtype of idiopathic multicentric Castleman disease. This syndrome should be considered in patients with severe, unexplained inflammation (e.g., C-reactive protein > 100 mg/L), anasarca, and lymphadenopathy. This syndrome should be considered in patients with severe, unexplained inflammation (e.g., C-reactive protein > 100 mg/L), anasarca, and lymphadenopathy. Diagnosis of Castleman disease requires careful clinicopathological correlation as histological findings alone may not be specific. Diagnosis of Castleman disease requires careful clinicopathological correlation as histological findings alone may not be specific. Radiographic adrenal abnormalities — including adrenalitis, adrenal hemorrhage, or adrenal masses — can serve as a diagnostic clue for TAFRO. Radiographic adrenal abnormalities — including adrenalitis, adrenal hemorrhage, or adrenal masses — can serve as a diagnostic clue for TAFRO. Once TAFRO is diagnosed, rapid initiation of an interleukin-6 inhibitor is required to prevent morbidity and death, and often results in excellent outcomes. Once TAFRO is diagnosed, rapid initiation of an interleukin-6 inhibitor is required to prevent morbidity and death, and often results in excellent outcomes. A 22-year-old White man presented to the emergency department with a 2-month history of progressive fatigue, intermittent abdominal pain, constipation, and dyspnea. He had gained 27 kg over 1 month, from a baseline of 82 kg. The fatigue was so severe he required a wheelchair. He had no fever, night sweats, travel history, skin changes, or joint pain. He was afebrile, with a blood pressure of 150/90 mm Hg, heart rate of 140 beats/min, respiratory rate of 24 breaths/min, and oxygen saturation of 98% on room air. He had 4+ pitting edema from the lower extremities to the mid-abdomen and decreased breath sounds at the lung bases. The emergency physician heard shifting dullness and dullness to percussion in the left anterior axillary line, suggestive of splenomegaly. He had no palpable lymphadenopathy, rash, or synovitis. Initial laboratory studies showed microcytic anemia, thrombocytopenia, renal failure, elevated alkaline phosphatase, very elevated C-reactive protein (CRP), and hypoalbuminemia (Table 1). A computed tomography (CT) scan revealed small diffuse lymphadenopathy involving the mediastinum, axillae, mesentery, and groin, measuring up to 2.2 cm in the short axis, as well as bilateral adrenal hemorrhage, pleural effusions, subcutaneous anasarca, ascites, and splenomegaly (Figure 1). An echocardiogram showed hyperdynamic left ventricular function and no structural heart disease to explain fluid in the interstitial space. Ascites and pleural fluids were transudative with no malignant cells. Table 1:Serum laboratory values from a 22-year-old man with idiopathic multicentric Castleman disease, TAFRO subtypeLaboratory testInitial valuePeak or nadirReference rangeHemoglobin, g/L11475140–180MCV, fL77.076.980.0–99.0Platelets, cells × 109/L7674150–400Leukocytes, cells × 109/L10.739.0*4.5–11.0Creatinine, μmol/L16719954–133eGFR, mL/min5041> 90Albumin, g/L221635–50CRP, mg/L173.8197.90–8Ferritin, μg/L66970230–300d-dimer, ng/mL23915254< 200Fibrinogen, g/L2.792.232.3–4.4aPTT, s37.742.926.1–35.3INR1.751.750.80–1.20AST, U/L43436–45ALP, U/L26844340–150GGT, U/L20120111–50Urine ACR, mg/mmol7.978.30–1.9LDH, U/L239302125–220Total IgG, g/L6.23.256.10–16.16γ globulins, g/L6.13.15–16Note: aPTT = activated partial thromboplastin time; ACR = albumin-to-creatinine ratio; ALP = alkaline phosphatase; AST = aspartate aminotransferase; CRP = C-reactive protein; eGFR = estimated glomerular filtration rate; GGT = γ-glutamyltransferase; Ig = immunoglobulin; INR = international normalized ratio; LDH = lactate dehydrogenase; MCV = mean corpuscular volume; TAFRO = thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly.*Leukocytosis was temporally related to initiation of glucocorticoids. Serum laboratory values from a 22-year-old man with idiopathic multicentric Castleman disease, TAFRO subtype Note: aPTT = activated partial thromboplastin time; ACR = albumin-to-creatinine ratio; ALP = alkaline phosphatase; AST = aspartate aminotransferase; CRP = C-reactive protein; eGFR = estimated glomerular filtration rate; GGT = γ-glutamyltransferase; Ig = immunoglobulin; INR = international normalized ratio; LDH = lactate dehydrogenase; MCV = mean corpuscular volume; TAFRO = thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly. Leukocytosis was temporally related to initiation of glucocorticoids. Portal venous computed tomography (A) axial and (B) coronal images of the abdomen of a 22-year-old man with Castleman disease, showing heterogeneous lesions arising from both adrenal glands (X), with surrounding fat stranding, as well as hyperdensity of the left adrenal gland (arrowhead). The patient was admitted to our general internal medicine service with a working diagnosis of lymphoma, and we consulted a hematologist for further investigation. Bone marrow biopsy showed grade 3/4 reticulin fibrosis with megakaryocytic hyperplasia, which we felt to be reactive rather than malignant. Flow cytometry was normal and next-generation sequencing showed no gene variants for myeloproliferative disorders. Serum protein electrophoresis and serum free light chains were normal. The patient underwent a technically difficult excisional biopsy of 2 inguinal lymph nodes (measuring 3.4 × 1.6 × 1.0 cm in aggregate), which revealed reactive changes with atypical architecture but no evidence of lymphoma or specific diagnosis. We deemed lymphoma unlikely. The remaining differential diagnosis included autoimmune diseases such as sarcoidosis and infection, including Epstein–Barr virus (EBV). Viral serologies for HIV, cytomegalovirus, EBV, hepatitis B virus and hepatitis C virus were negative, and the infectious disease specialist determined an underlying infection to be unlikely. Autoimmune investigations were negative or normal for antinuclear antibodies, extractable nuclear antigens, antineutrophil cytoplasmic antibodies, rheumatoid factor, anticyclic citrullinated peptide, and complements. A rheumatologist suggested a 18F fluorodeoxyglucose (FDG) positron emission tomography/CT scan (Figure 2) to further investigate potential sarcoidosis, which demonstrated low-avidity lymph nodes but no specific findings of sarcoidosis. Our remaining considerations included the vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome, or autoimmune lymphoproliferative syndrome (ALPS). A medical geneticist arranged whole-exome sequencing (GenomeSeqDx Trio), which showed no pathologic mutations. (A) Whole-body 18F fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (CT) of a 22-year-old man with Castleman disease, demonstrating FDG-avid lymph nodes within the retroperitoneum (arrows) and ascites (*) on axial imaging. (B) Coronal CT image shows splenomegaly (15 cm in craniocaudal dimension) (X), ascites (*), and pleural effusion (^). The patient was in left lateral decubitus position because of orthopnea. In the patient’s fourth week of hospital admission, still without a diagnosis, he developed worsening anemia at a nadir of 75 (reference range 140–180) g/L and diuretic-resistant anasarca, resulting in 30 L of ascites and 15 L of pleural fluid drained from each lung over 3 weeks via in-dwelling catheters placed by our general medicine team. We started hydrocortisone (100 mg intravenously every 6 h) empirically for his systemic inflammatory condition. He improved quickly while on corticosteroids, with decreasing fluid output from third-space catheters, improvement in cytopenias, and decreasing CRP; we switched him to oral prednisone (100 mg/d, 1 mg/kg). Temporary clinical improvement on corticosteroids afforded us the opportunity to revisit the underlying cause of the patient’s lymphadenopathy, anasarca, cytopenias, renal dysfunction, and systemic inflammation. Among the clonal malignant lymphomas, EBV-associated lymphoma and angioimmunoblastic T-cell lymphoma are known to present with systemic inflammation and challenging histology. However, the lack of histologic evidence of lymphoma on excisional biopsy and excellent response to corticosteroid monotherapy made these entities less likely. The lack of typical sarcoid end-organ involvement (e.g., interstitial lung disease, erythema nodosum, uveitis, hypercalcemia) and non-caseating granulomas on lymph node and bone marrow biopsy ruled out sarcoidosis. Among the histiocyte disorders, Rosai–Dorfman–Destombes disease was most likely, but would not typically cause anasarca, and expert review of the biopsies showed no evidence of clonal histiocytosis. With the markedly elevated CRP, we considered cytokine storm syndromes such as hemophagocytic lymphohistiocytosis and adult-onset Still disease; however, these both present with a serum ferritin level well over 3000 μg/L and were thus unlikely, given his ferritin reached only 702 (reference range 30–300) μg/L. One condition that can present with prominent lymphadenopathy, nonspecific histology, and severe inflammation is idiopathic multicentric Castleman disease, particularly the thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly (iMCD-TAFRO) subtype. Specimens of the patient’s lymph nodes were therefore reviewed in the context of his clinical findings and indeed revealed characteristic features of regressed germinal centres with onion skinning and foci of hypervascularity with surrounding lymphocytes and plasma cells (Figure 3). Lymph node histology of a 22-year-old man with idiopathic multicentric Castleman disease, thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly (TAFRO) subtype, demonstrating Castleman-like features, including (A) regressed germinal centres with onion skinning (arrow) and (B) foci of hypervascularity (arrows). Hematoxylin and eosin stain, 20× magnification for panel A, 40× magnification for panel B. We diagnosed iMCD-TAFRO and started the patient on directed therapy with the interleukin (IL)-6 inhibitor siltuximab. He rapidly improved and was discharged from hospital after a 2-month hospital admission and tapered off corticosteroids. He remains asymptomatic and fully functional in day-to-day life, with a plan to continue intravenous siltuximab infusions every 3 weeks indefinitely or until disease relapse. Discussion Castleman disease is a rare, nonmalignant lymphoproliferative disorder characterized by histopathological changes in lymph nodes, which often need to be connected to relevant clinical findings and laboratory markers for firm diagnosis.1,2 Clinical presentation ranges from minimally symptomatic unicentric Castleman disease to critical illness in iMCD-TAFRO. In North America, the annual incidence of Castleman disease is estimated at 3–4 cases per million people, with about 75% of cases presenting as unicentric Castleman disease, with the remainder presenting as multicentric Castleman disease; iMCD-TAFRO occurs in about 1 in a million people.3 In unicentric Castleman disease, a single lymph node region is affected and is often cured with surgical excision. By contrast, multicentric Castleman disease is a cytokine storm syndrome and involves lymphadenopathy of multiple body regions with associated systemic inflammatory symptoms and laboratory abnormalities.2,4 Multicentric Castleman disease is further divided into 2 types, 1 associated with human herpesvirus-8 (HHV-8), which is often found in people who are positive for HIV and is typically treated with rituximab, and HHV-8–negative multicentric Castleman disease, also referred to as iMCD. The 3 subtypes of iMCD are iMCD not otherwise specified; iMCD-TAFRO; and the newest subtype, iMCD idiopathic plasmacytic lymphadenopathy.5 Among the subtypes of iMCD, iMCD-TAFRO is the most rapidly progressive and most challenging to recognize.1,4 This subtype is rare and typically occurs in the third to fifth decade of life with a male preponderance; most patients in the literature are of East Asian descent but it can occur in any racial or ethnic group. Patients present with thrombocytopenia; anasarca with pleural effusions or ascites; fever or elevated CRP; reticulin fibrosis on bone marrow biopsy (often associated with megakaryocyte hyperplasia and mild hemophagocytosis); renal failure; organomegaly; and diffuse, small-volume (1–2 cm in short axis) low FDG–avid lymphadenopathy. Although other types of iMCD often present with polyclonal hypergammaglobulinemia, in TAFRO, levels of γ globulins and immunoglobulin G are typically normal or only mildly elevated.6 Other features of iMCD-TAFRO include elevated alkaline phosphatase with relatively normal levels of transaminases. Clinicopathological correlation is critical for diagnosis of iMCD-TAFRO, as the small lymph nodes yield little diagnostic tissue and many of the histological (e.g., regressed germinal centres, hypervascularity, polyclonal increase in plasma cells) and bone marrow (e.g., reticulin fibrosis, hypercellularity) findings can also be seen in reactive conditions such as infection and autoimmune disease.7 Clear communication between clinicians and pathologists is critical, both for correlation and to exclude disease mimics such as lymphoma, hemophagocytic lymphohistiocytosis, infection, and autoimmune diseases. Another diagnostic clue illustrated in this case is the presence of radiographic adrenal abnormalities, including hemorrhage, adrenalitis, necrosis, or masses, as seen in 7 of 13 patients from a Japanese study.8 We suspected adrenal hemorrhage in our patient based on the visibility of heterogeneous adrenal lesions, which spontaneously reduced in size on repeat CT with adrenal washout. Adrenal abnormalities on CT may be seen early in the disease course, foreshadowing onset of overt iMCD-TAFRO, and may be a useful early diagnostic clue.9,10 As in our patient, adrenal hemorrhage is typically asymptomatic, without associated adrenal insufficiency, and may resolve spontaneously. Rapid initiation of systemic therapy is essential in iMCD-TAFRO. Castleman disease is largely driven by IL-6, and IL-6 inhibition with siltuximab or tocilizumab is considered first-line therapy. Patients with refractory disease may require cytotoxic chemotherapy, other cytokine inhibitors (e.g., IL-1 or tumour necrosis factor inhibitors), mammalian target of rapamycin inhibitors, or a combination thereof.4,9 Corticosteroids are often used as an adjunctive therapy, although monotherapy is not advised, and complete responses to steroid monotherapy, as initially obtained in this patient, are uncommon. The key to diagnosing Castleman disease is a high index of suspicion and awareness of this disease when confronted with lymphadenopathy and a systemic inflammatory response that cannot be explained by malignant disease, autoimmune disease, or infection. Diagnosis is done clinicopathologically, and must integrate imaging, laboratory studies, and lymph node histology. Patients should be referred to a hematologist or other specialist with experience in Castleman disease to definitively establish the diagnosis. Identifying this disease is important because it is associated with a high degree of morbidity and death. Treatment with an IL-6 inhibitor such as siltuximab often results in excellent outcomes.1